Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Autologous BCMA CAR-T(The First Affiliated Hospital of Xiamen University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Autologous BCMA CAR-T(The First Affiliated Hospital of Xiamen University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP
9 min read
Frunexian Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Frunexian: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Pegarginase(Bio-Cancer Treatment International Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Pegarginase(Bio-Cancer Treatment International Ltd.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, ma
9 min read
Qinwei Capsule Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Qinwei Capsule: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BI 1584862 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
BI 1584862: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
QG101-23-0 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
QG101-23-0: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ACI-24 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
ACI-24: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
HY-1608 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
HY-1608: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Huayu Sanjie Tablets Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Huayu Sanjie Tablets: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
YH-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
YH-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Elenagen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Elenagen: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PRT-2761 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
PRT-2761: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.